A section of the Ozempic users are reporting a sharp drop—or surge—in libido, with experts exploring how GLP-1 medications ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction.

Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...

A 14-month randomized trial in older African American adults with obesity found that adopting a Mediterranean diet, with or ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which ...